PHVS/ 10/08/2025 · 4:25 PM BofA Upgrades Pharvaris: What Investors Need to Know BofA upgrades Pharvaris to Neutral ($27 target). Unique oral drug for angioedema treatment, but current price assumes success of upcoming data.
